Preclinical activity of nanoliposomal irinotecan is governed by tumor deposition and intratumor prodrug conversion
Kalra, Ashish V, Kim, Jaeyeon, Klinz, Stephan G, Paz, Nancy, Cain, Jason, Drummond, Daryl C, Nielsen, Ulrik B, Fitzgerald, Jonathan B
Published in Cancer research (Chicago, Ill.) (01.12.2014)
Published in Cancer research (Chicago, Ill.) (01.12.2014)
Get full text
Journal Article
Extended topoisomerase 1 inhibition through liposomal irinotecan results in improved efficacy over topotecan and irinotecan in models of small-cell lung cancer
Leonard, Shannon C, Lee, Helen, Gaddy, Daniel F, Klinz, Stephan G, Paz, Nancy, Kalra, Ashish V, Drummond, Daryl C, Chan, Daniel C, Bunn, Paul A, Fitzgerald, Jonathan B, Hendriks, Bart S
Published in Anti-cancer drugs (01.11.2017)
Published in Anti-cancer drugs (01.11.2017)
Get more information
Journal Article
Abstract 2065: Magnetic resonance imaging with an iron oxide nanoparticle demonstrates the preclinical feasibility of predicting intratumoral uptake and activity of MM-398, a nanoliposomal irinotecan (nal-IRI)
Kalra, Ashish V., Spernyak, Joseph, Kim, Jaeyeon, Sengooba, Arnold, Klinz, Stephan, Paz, Nancy, Cain, Jason, Kamoun, Walid, Straubinger, Ninfa, Qu, Yang, Trueman, Sheryl, Bayever, Eliel, Nielsen, Ulrik, Drummond, Daryl, Fitzgerald, Jonathan, Straubinger, Robert
Published in Cancer research (Chicago, Ill.) (01.10.2014)
Published in Cancer research (Chicago, Ill.) (01.10.2014)
Get full text
Journal Article